T1	Participants 405 577	Women aged 50 to 80 years received raloxifene for 96 weeks and were then randomized to continue raloxifene (group 1, n=20) or placebo (group 2, n=20) for a further 96 weeks
T2	Participants 371 403	postmenopausal, osteopenic women
